Quotient Sciences Recognized as a Winner of 2025 CDMO Leadership Awards
Read More11 - 15 of 154 results
In this article by The Medicine Maker, Dr. Asma Patel, VP of Integrated Development Services at Quotient Sciences discusses how accelerating first-in-human (FiH) clinical trials is crucial in drug development, especially for orphan drugs tr...
Learn more
Modified-Release Formulations and Complex Challenges in Drug Development
Learn more
Nanomerics phase 1 study has commenced with Quotient Sciences. The first volunteers for the Phase I trial of OC134 has started at Quotient Sciences - Nottingham.
Learn more
Nanomerics announced the end of dosing with Quotient Sciences. All volunteers completed 28 consecutive days of administration in its OC134 Phase I trial – the SUNLIGHT trial. Learn about the study.
Learn more
As part of the company’s ongoing commitments to enhancing its environmental, governance, and sustainability (ESG) practices, Quotient Sciences has issued its inaugural ESG report with data accumulated from 2023.
Learn more
